In their second collaboration in a little over a year, Regeneron Pharmaceuticals has entered into a five-year alliance with Alnylam Pharmaceuticals to develop RNA interference therapies for 30 targets for the treatment of ocular and central nervous system diseases. The companies will also collaborate to develop therapies for liver diseases including an effort to evaluate anti-C5 antibody-siRNA combinations.The deal comes as Regeneron looks to hedge the impending competitive risk for Eylea® (aflibercept) from Novartis’ brolucizumab and as Alnylam concludes the research and option phase of its long-term alliance with Sanofi.